Trial Profile
A Single-blind, Single-center, Randomized, Active-controlled, Parallel Group, Phase I Study to Evaluate the Safety and Immunogenicity of Intramuscular Single Injection With LBVE013 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), LBVE014 (Pneumococcal 14-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) or Prevnar13 in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2017
Price :
$35
*
At a glance
- Drugs LBVE 013 (Primary) ; LBVE 014 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors LG Life Sciences
- 23 Jun 2017 Status changed from not yet recruiting to completed.
- 03 Oct 2016 New trial record